In a translational study, it was shown that the double mutations hyperactivate PI3K signaling with increased tumor growth in preclinical models and also early clinical trial data showed that breast cancers harboring double mutations were more sensitive and responded better to PI3K inhibitors than those with a single mutation. This evidence concerns the gene PIK3CA and breast cancer.